SCHEMBL2805634

SCHEMBL2805634

O=C(Nc1cccc2ccccc12)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.61
TAAR1 Q96RJ0 1/20 0.61
ALDH1A1 P00352 7/20 0.53
HSD17B10 Q99714 6/20 0.53
KMT2A Q03164 1/20 0.51
POLB P06746 2/20 0.48
LMNA P02545 2/20 0.48
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
TSHR P16473 1/20 0.47
PAK1 Q13153 2/20 0.47
TRPV1 Q8NER1 3/20 0.46
HRH4 Q9H3N8 1/20 0.46
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804401 0.87 PAK1 (0.59) KDM4ETAAR1ALDH1A1POLBPAK1
SCHEMBL2806132 0.85 PAK1 (0.44) KDM4ETAAR1PAK1TRPV1
SCHEMBL2486602 0.84 RAB9A (0.55) KDM4EALDH1A1KMT2AMAPK1PAK1
SCHEMBL2804570 0.83 PAK1 (0.49) KDM4ETAAR1POLBPAK1TRPV1
SCHEMBL2804559 0.83 TRPV1 (0.46) KDM4EHSD17B10PAK1TRPV1NPSR1
SCHEMBL2485492 0.83 RAB9A (0.47) KDM4ETAAR1PAK1TRPV1
SCHEMBL2804020 0.83 PDGFRB (0.47) KDM4ETAAR1ALDH1A1HSD17B10KMT2A
SCHEMBL2807735 0.82 FAAH (0.45) KDM4ETAAR1ALDH1A1HSD17B10KMT2A
SCHEMBL2808039 0.82 PAK1 (0.46) KDM4ETAAR1PAK1TRPV1
SCHEMBL2805002 0.79 PAK1 (0.60) KDM4EALDH1A1KMT2ALMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 KDM4E 1334/4885TAAR1 4868/4885ALDH1A1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.